F S&P 500
5,061.25 +13.75 (+0.27%) F Dow Jones
38,541.00 +73.00 (+0.19%) F Nasdaq
17,406.25 +56.25 (+0.32%) E-mini Russell 2000 Index Futur
1,982.40 -0.20 (-0.01%) Petróleo
81.51 -0.39 (-0.48%) Oro
2,314.50 -31.90 (-1.36%)
aTyr Pharma, Inc. (LIFE)
Fuera de horario:
aTyr Pharma, Inc.
10240 Sorrento Valley Road
Suite 300
San Diego, CA 92121
United States
858 731 8389
https://www.atyrpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 56
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Sanjay S. Shukla M.D., M.S. | President, CEO & Director | 768.18k | N/D | 1972 |
| Ms. Jill M. Broadfoot | Chief Financial Officer | 544.75k | N/D | 1962 |
| Ms. Nancy E. Denyes Krueger | General Counsel & Corporate Secretary | 518.2k | N/D | 1968 |
| Xiang-Lei Yang Ph.D. | Founder | N/D | N/D | N/D |
| Ms. Ashlee Dunston | Director of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Mr. Peter Villiger | Vice President of Corporate Development | N/D | N/D | N/D |
| Ms. Danielle Campbell | VP of Human Resource | N/D | N/D | N/D |
| Dr. Leslie Nangle Ph.D. | Vice President of Research | N/D | N/D | N/D |
| Dr. Ying J. Buechler Ph.D. | Executive Director of Biologics Development & Manufacturing | N/D | N/D | N/D |
| Dr. David J. King Ph.D. | Scientific Consultant | 327.31k | N/D | 1959 |
Descripción
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Gestión corporativa
La calificación ISS Governance QuickScore de aTyr Pharma, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
